Joseph Thome
Stock Analyst at TD Cowen
(1.62)
# 3,433
Out of 5,154 analysts
21
Total ratings
44.44%
Success rate
-3.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $525 → $575 | $478.16 | +20.25% | 3 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $115 → $117 | $86.30 | +35.57% | 2 | Feb 26, 2026 | |
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $62.82 | +0.29% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $6.19 | +61.55% | 1 | Oct 31, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $76.87 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $28.34 | - | 1 | Nov 25, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $30.24 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $28.63 | +18.76% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.01 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi Therapeutics | Initiates: Outperform | n/a | $1.48 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.94 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.55 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $162.33 | -19.92% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.44 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.58 | - | 1 | Nov 23, 2021 |
United Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $525 → $575
Current: $478.16
Upside: +20.25%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $115 → $117
Current: $86.30
Upside: +35.57%
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $62.82
Upside: +0.29%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.19
Upside: +61.55%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $76.87
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $28.34
Upside: -
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $30.24
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $28.63
Upside: +18.76%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.01
Upside: -
Metagenomi Therapeutics
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.48
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.94
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $162.33
Upside: -19.92%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.44
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.58
Upside: -